These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32220885)

  • 21. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.
    Hakimi AA; Furberg H; Zabor EC; Jacobsen A; Schultz N; Ciriello G; Mikklineni N; Fiegoli B; Kim PH; Voss MH; Shen H; Laird PW; Sander C; Reuter VE; Motzer RJ; Hsieh JJ; Russo P
    J Natl Cancer Inst; 2013 Dec; 105(24):1862-70. PubMed ID: 24285872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.
    Zhang Y; Zhu X; Qiao X; Sun L; Tian Y; Yang Y; Zhao Y; Liu C
    Int J Med Sci; 2020; 17(17):2819-2825. PubMed ID: 33162809
    [No Abstract]   [Full Text] [Related]  

  • 23. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
    Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
    Chong TW; Goh FY; Sim MY; Huang HH; Thike AA; Lim WK; Teh BT; Tan PH
    J Clin Pathol; 2015 Mar; 68(3):200-5. PubMed ID: 25477528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parallel evolution of tumour subclones mimics diversity between tumours.
    Martinez P; Birkbak NJ; Gerlinger M; McGranahan N; Burrell RA; Rowan AJ; Joshi T; Fisher R; Larkin J; Szallasi Z; Swanton C
    J Pathol; 2013 Aug; 230(4):356-64. PubMed ID: 23716380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
    Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
    Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease.
    Moynihan MJ; Sullivan TB; Burks E; Schober J; Calabrese M; Fredrick A; Kalantzakos T; Warrick J; Canes D; Raman JD; Rieger-Christ K
    Urol Oncol; 2020 Oct; 38(10):799.e11-799.e22. PubMed ID: 32534961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.
    Ito T; Pei J; Dulaimi E; Menges C; Abbosh PH; Smaldone MC; Chen DY; Greenberg RE; Kutikov A; Viterbo R; Uzzo RG; Testa JR
    J Urol; 2016 Apr; 195(4 Pt 1):852-8. PubMed ID: 26602888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome.
    Na JC; Nagaya N; Rha KH; Han WK; Kim IY
    Clin Genitourin Cancer; 2019 Aug; 17(4):299-305.e1. PubMed ID: 31204211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
    Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
    Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
    Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
    Luo L; Zhou H; Su H
    BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integral Analysis of the RNA Binding Protein-associated Prognostic Model for Renal Cell Carcinoma.
    Qin X; Liu Z; Yan K; Fang Z; Fan Y
    Int J Med Sci; 2021; 18(4):953-963. PubMed ID: 33456353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.
    Weng S; DiNatale RG; Silagy A; Mano R; Attalla K; Kashani M; Weiss K; Benfante NE; Winer AG; Coleman JA; Reuter VE; Russo P; Reznik E; Tickoo SK; Hakimi AA
    Eur Urol; 2021 Apr; 79(4):468-477. PubMed ID: 33046271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.
    Peng CH; Liao CT; Ng KP; Tai AS; Peng SC; Yeh JP; Chen SJ; Tsao KC; Yen TC; Hsieh WP
    Oncotarget; 2015 Aug; 6(23):19891-906. PubMed ID: 26087196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.